Table 2

Univariable and multivariable analyses for ePFS in the overall population

Characteristics	Univariable analyses			Multivariable analyses
Characteristics	HR	95% CI	P value	HR	95% CI	P value
Age ≥70 years versus <70 years	1.43	0.93 to 2.18	0. 07	1.02	0.99 to 1.04	0.12
ECOG PS 1 versus 0	1.45	0.89 to 2.33	0.08	2.04	1.11 to 3.72	0.02
Synchronous versus metachronous	1.31	0.87 to 1.98	0.24	–	–	–
Resected primary tumour versus unresected	0.84	0.61 to 1.15	0.26	–	–	–
Left versus right primary	0.89	0.64 to 1.26	0.52	–	–	–
Nodal involvement versus no involvement	1.55	1.08 to 2.23	0.03	1.48	0.91 to 2.40	0.12
Baseline CEA level >200 versus ≤200 ng/mL	1.19	0.80 to 1.77	0.37	–	–	–
Number of liver metastases ≥4 versus <4	1.67	1.22 to 2.29	0.003	1.83	1.15 to 2.90	0.01
Liver metastases maximum diameter >30 versus ≤30 mm	1.35	0.96 to 1.86	0.09	1.98	1.23 to 3.20	0.005
Bilobar involvement yes versus no	1.14	0.82 to 1.58	0.44	–	–	–
Liver involvement >6 versus ≤6 segments	1.40	0.94 to 2.09	0.06	0.69	0.36 to 1.33	0.27
RAS/BRAF mutation versus RAS/BRAF wild type	1.11	0.82 to 1.51	0.67	–	–	–
MSI high versus MSS	2.41	0.42 to 13.88	0.03	-*	-*	-*
Triplet versus doublet induction	1.20	0.89 to 1.62	0.22	–	–	–
Anti-EGFR versus anti-VEGF	1.04	0.73 to 1.47	0.37	–	–	–
Liver secondary resection	0.39	0.26 to 0.59	< 0.001	0.37	0.21 to 0.65	< 0.001
Liver retreatments	0.27	0.19 to 0.39	< 0.001	–	–	–

*Too small sample size for multivariable model
†Bold values represent statistically significant values.
Anti-EGFR, anti-epidermal growth factor receptor; Anti-VEGF, anti-vascular endothelial growth factor receptor; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability; MSS, microstatellite stable; PS, Performance Status; ePFS, extrahepatic progression-free survival.